EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Development and Validation of a Novel Four Gene-Pairs Signature for Predicting Prognosis in DLBCL Patients

Atsushi Tanabe iD, Jerry Ndzinu, Hiroeki Sahara

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252312807 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Atsushi Tanabe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Highly-Advanced Veterinary Medical Technology, Veterinary Teaching Hospital, Azabu University, 1-17-71 Fuchinobe Chuo-ku, Sagamihara 25…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma. Because individual clinical outcomes of DLBCL in response to standard therapy differ widely, new treatment strategies are being investigated to improve therapeutic efficacy. In this study, we identified a novel signature for stratification of DLBCL useful for prognosis prediction and treatment selection. First, 408 prognostic gene sets were selected from approximately 2500 DLBCL samples in public databases, from which four gene-pair signatures consisting of seven prognostic genes were identified by Cox regression analysis. Then, the risk score was calculated based on these gene-pairs and we validated the risk score as a prognostic predictor for DLBCL patient outcomes. This risk score demonstrated independent predictive performance even when combined with other clinical parameters and molecular subtypes. Evaluating external DLBCL cohorts, we demonstrated that the risk-scoring model based the four gene-pair signatures leads to stable predictive performance, compared with nine existing predictive models. Finally, high-risk DLBCL showed high resistance to DNA damage caused by anticancer drugs, suggesting that this characteristic is responsible for the unfavorable prognosis of high-risk DLBCL patients. These results provide a novel index for classifying the biological characteristics of DLBCL and clearly indicate the importance of genetic analyses in the treatment of DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseHumansPrognosisFemaleMaleGene Expression ProfilingBiomarkers, TumorGene Expression Regulation, NeoplasticMiddle AgedTranscriptomeAged

Stichwörter der Autor:innen

diffuse large B-cell lymphomadrug sensitivitygene signatureprognosispublic database

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Laboratory of Highly-Advanced Veterinary Medical Technology, Veterinary Teaching Hospital, Azabu University, 1-17-71 Fuchinobe Chuo-ku, Sagamihara 252-5201, Kanagawa, Japan.
  • Laboratory of Biology, Azabu University School of Veterinary Medicine, 1-17-71 Fuchinobe Chuo-ku, Sagamihara 252-5201, Kanagawa, Japan.
  • Department of Research and Development (R&D), Malignant Tumor Treatment Technologies, Inc., 130-42 Nagasone, Kita-ku, Sakai 591-8025, Osaka, Japan.

ORCID-Profile: Atsushi Tanabe

Zitieren

APA

Tanabe, A., Ndzinu, J., & Sahara, H. (2024). Development and Validation of a Novel Four Gene-Pairs Signature for Predicting Prognosis in DLBCL Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252312807

Vancouver

Tanabe A, Ndzinu J, Sahara H. Development and Validation of a Novel Four Gene-Pairs Signature for Predicting Prognosis in DLBCL Patients. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252312807

BibTeX
@article{Tanabe2024,
  author = {Tanabe, Atsushi and Ndzinu, Jerry and Sahara, Hiroeki},
  title = {Development and Validation of a Novel Four Gene-Pairs Signature for Predicting Prognosis in DLBCL Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252312807}
}
Kostenlos starten →